glp 1r retatrutide RETATRUTIDE: A Medication for Diabetes and Weight Loss Retatrutide | GLP-1R/GIPR/GCGR ligand |

The biggest reduction in obesity is found among those aged 40 to 49 and those aged 50 to 64, which are also the age groups with the greatest current rates of usage of GLP-1 injectables for weight loss purposes and the greatest increases in use of those injectables since the first quarter of 2024

Our latest survey shows that while 57% of employers cover these treatments for weight loss, cost concerns remain a major hurdle

Phase II Jastreboff 2023 NEJM: -24.2% at 12mg/48w for retatrutide vs SURMOUNT-1 Jastreboff 2022: -20.9% at 15mg/72w for tirzepatide

FDA Safety Announcements for Metformin

Al utilizar de una forma ms eficiente las reservas de grasa del cuerpo, se optimizar la prdida de grasa y se preservar en mayor medida la masa muscular, por lo podremos obtener una optimizacin de la composicin corporal